

OncoTherapy Science, Inc.

January 31, 2019

Announcement of the Initiation of Phase I Clinical Study of Cancer-Specific Peptide Vaccine  
S-588210 for Solid Tumor Patients

OncoTherapy Science, Inc. (President & CEO: Kyoko Fujiya; hereinafter, “OncoTherapy”) announces that a Phase I clinical study of cancer-specific peptide vaccine S-588210 whose intellectual property rights are owned by OncoTherapy and was exclusively licensed to Shionogi & Co., Ltd. (Head office: Chuo-ku, Osaka, President & CEO: Isao Teshirogi), will be initiated in United Kingdom. This study is designed to evaluate safety, tolerability and immune response after administration of S-588210 in patients with solid tumor.

S-588210 is the cocktail peptide vaccine which contains multiple peptides targeting the cancer-specific antigens. These antigens were identified through genome-wide gene expression profile of human cancer which are highly expressed in cancer cells. OncoTherapy has been and will facilitate the strategic dialogue with our licensing-out partners, and enforces the indirect and logistic supports for clinical development conducted by these partners.